Empowering Oncology Teams to Improve Care Quality for Women with Advanced or Metastatic HR+/HER2- Breast Cancer
Intended Audience: Physicians, Nurse Practitioners, Physician Assistants, Pharmacists, and Nurses
Real-world insights into the challenges of integrating CDK4/6 inhibitors for patients with HR+/HER2- advanced or metastatic breast cancer were garnered during a quality improvement initiative conducted at two large oncology health systems. In this webcast, leading breast cancer experts share aggregated findings, strategies to integrate best practices for evidence-based and guideline-compliant care, and patient-centered approaches to treatment decision-making and monitoring.
Physicians completing this program will earn AMA PRA Category 1 Credit™ classified as Enduring material.
Pharmacists completing this program will earn Home Study credit in Disease State Mgmt/Drug therapy (H01).